Duncan-Williams Previews 2Q Earnings for Vascular Solutions

Duncan-Williams has published a research report on Vascular Solutions VASC previewing earnings for the second quarter. In the report, Duncan-Williams wrote, "Our Q2:11 Catheters revenue estimate is $13.5 million. This represents approximately 31% growth compared to the same period last year. Catheters revenue represents approximately 60% of total revenue for Q2:11. We look for sales of the GuideLiner catheter and the Pronto catheter to drive revenue growth in Q2:11. We estimate 2011 Catheters revenue of approximately $52.6 million. This represents 25% growth compared to 2010." Duncan-Williams rated Vascular Solutions a BUY with a price target of $15.00. Vascular Solutions closed Thursday at $13.35.